TY - JOUR
T1 - Breast cancer circulating biomarkers
T2 - advantages, drawbacks, and new insights
AU - Ravelli, Andrea
AU - Reuben, James M.
AU - Lanza, Francesco
AU - Anfossi, Simone
AU - Cappelletti, Maria Rosa
AU - Zanotti, Laura
AU - Gobbi, Angela
AU - Senti, Chiara
AU - Brambilla, Paola
AU - Milani, Manuela
AU - Spada, Daniele
AU - Pedrazzoli, Paolo
AU - Martino, Massimo
AU - Bottini, Alberto
AU - Generali, Daniele
N1 - Publisher Copyright:
© 2015, International Society of Oncology and BioMarkers (ISOBM).
PY - 2015/8/1
Y1 - 2015/8/1
N2 - As of today, the level of individualization of cancer therapies has reached a level that 20 years ago would be considered visionary. However, most of the diagnostic, prognostic, and therapy-predictive procedures which aim to improve the overall level of personalization are based on the evaluation of tumor tissue samples, therefore requiring surgical operations with consequent low compliance for patients and high costs for the hospital. Hence, the research of a panel of circulating indicators which may serve as source of information about tumor characteristics and which may be obtainable by a simple withdrawal of peripheral blood today represents a growing field of interest. This review aims to objectively summarize the characteristics of the currently available breast cancer circulating biomarkers, also providing an overview about the multitude of novel potential soluble predictors which are still under evaluation. Specifically, the usefulness of a so-called “liquid biopsy” will be discussed in terms of improvements of diagnosis, prognosis, and therapy-prediction, but an overview will be given also on the potentiality of the molecular characterization arising from the isolation of circulating biomarkers and cells. Although this review will focus on the specific case of the breast, in the future liquid biopsies will hopefully be available for virtually any type of neoplasms.
AB - As of today, the level of individualization of cancer therapies has reached a level that 20 years ago would be considered visionary. However, most of the diagnostic, prognostic, and therapy-predictive procedures which aim to improve the overall level of personalization are based on the evaluation of tumor tissue samples, therefore requiring surgical operations with consequent low compliance for patients and high costs for the hospital. Hence, the research of a panel of circulating indicators which may serve as source of information about tumor characteristics and which may be obtainable by a simple withdrawal of peripheral blood today represents a growing field of interest. This review aims to objectively summarize the characteristics of the currently available breast cancer circulating biomarkers, also providing an overview about the multitude of novel potential soluble predictors which are still under evaluation. Specifically, the usefulness of a so-called “liquid biopsy” will be discussed in terms of improvements of diagnosis, prognosis, and therapy-prediction, but an overview will be given also on the potentiality of the molecular characterization arising from the isolation of circulating biomarkers and cells. Although this review will focus on the specific case of the breast, in the future liquid biopsies will hopefully be available for virtually any type of neoplasms.
KW - Breast cancer circulating biomarkers
KW - Breast cancer liquid biopsy
KW - Circulating DNA
KW - Circulating microRNA
KW - Circulating tumor cells
KW - Microvesicles and exosomes
UR - http://www.scopus.com/inward/record.url?scp=84947125932&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84947125932&partnerID=8YFLogxK
U2 - 10.1007/s13277-015-3944-7
DO - 10.1007/s13277-015-3944-7
M3 - Review article
C2 - 26307395
AN - SCOPUS:84947125932
SN - 1010-4283
VL - 36
SP - 6653
EP - 6665
JO - Tumor Biology
JF - Tumor Biology
IS - 9
ER -